-
FDA Approves Ustekinumab-Stba, Biosimilar to Stelara, for Pediatric Patients With PsO or PsA
16 Jun 2025 16:53 GMT
… Janssen Pharmaceuticals), for the treatment of plaque psoriasis (PsO … December 2024, the FDA approved the biosimilar in … blind phase 3 clinical trial (NCT04673786) that assessed … infection site erythema, vulvovaginal candidiasis/mycotic infection, bronchitis …
-
Celltrion Announces U.S. FDA Approval Of Additional Presentation Of STEQEYMA® (Ustekinumab-Stba), Expanding Dosing Options For Pediatric Patients
16 Jun 2025 00:47 GMT
… treatment continuity for patients.
In December 2024, the FDA … or clinically significant infection develop, discontinue STEQEYMA until … , injection site erythema, vulvovaginal candidiasis/mycotic infection, bronchitis … pipeline with novel drugs to push the …
-
Sano Women's Health Raises Funds To Advance Phase 2 Clinical Trials For Novel RVVC Treatment
09 Jun 2025 14:08 GMT
… company focused on innovative treatments for underserved women… trials for a first-in-class treatment targeting recurrent vulvovaginal candidiasis … RVVC who deserve better treatment options," said … FDA to advance this much needed product.
Phase 2 trials …
-
Treatment of Oral Lichen Planus (SIDeMaST, 2025)
03 Jun 2025 15:05 GMT
… against local candidiasis with topical or systemic antifungal drugs (eg, miconazole … , nystatin, or fluconazole) should be considered. If stomatopyrosis develops … is recommended as first-line treatment; if disease is extensive, …
-
European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD
03 Jun 2025 14:19 GMT
… HD21 trial aims to evaluate a new treatment regimen … pneumonia and oral candidiasis have been reported … if hyperglycemia develops, administer anti-hyperglycemic medications as clinically … any prescription drugs including the ones under development.
Footnotes: …
-
Scynexis says GSK on hook for $10M payment after phase 3 Brexafemme trial starts back up
29 May 2025 02:04 GMT
… Brexafemme (ibrexafungerp), the developer of the treatment, Scynexis, has … need for new treatments for invasive candidiasis, particularly for … 2021, the FDA approved Brexafemme for vulvovaginal candidiasis (VVC), which … 2023, the MARIO trial was put on hold …
-
US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection
27 May 2025 11:47 GMT
… treatment with HADLIMA, including the possible development … including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and … , rationing prescription medications, reducing the … ;/www.fda.gov/drugs/biosimilars…
-
Vaginal and Vulval Inflammatory Diseases Treatment Market to Surpass USD 5,500.7 Million by 2035 | FMI
27 May 2025 05:25 GMT
… bacterial vaginosis, vulvovaginal candidiasis, lichen sclerosis, … across both developed and developing economies. Emerging … and homeopathic remedies, while pharmaceutical …
• Others
By Treatment:
• Anti-Itch Medications
• Corticosteroid Ointments
…
-
Celltrion's YUFLYMA® (adalimumab-aaty) receives FDA interchangeability designation for all its approved dosage forms and strengths
22 May 2025 04:03 GMT
… including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and … who develops a new infection during treatment with … biologic disease-modifying antirheumatic drugs (DMARDs) (e. … reported during clinical trials for patients treated …
-
Global Yeast Infection Treatment Market: Key Drivers, Trends, Growth Opportunities, And Forecast For 2025-2034
19 May 2025 11:38 GMT
… development and approval of new antifungal medications.
Is the Yeast Infection Treatment … on natural and herbal remedies, and a focus on … , by treatment medical treatment, surgery, by indication genital candidiasis, invasive candidiasis, oropharyngeal …
About
© 1995-2025